Any references to product characteristics, including but not limited to stability, preservation, or composition, are provided solely for general informational purposes within a research context and do not imply suitability for any other use
FDA-approved commercially available medications are always considered when clinically appropriate.
The prevailing understanding is that BPC 157s systemic action is sufficient, making SubQ injections effective, safer, and easier to administer for virtually all applications
Interestingly, all these studies have reported only downregulation of specific miRNAs which lead to an increased expression of IGF1R in osteosarcoma
While this sounds great, it's crucial to remember the limitations
IGF-1 LR3 lowers blood glucose